NEW YORK (GenomeWeb News) – Eutropics Pharmaceuticals has received two new Small Business Innovation Research award contracts totaling $1.7 million from the National Cancer Institute to fund development of two biomarker-based companion diagnostic assays for use in cancer treatment.

Eutropics has signed a phase II contract valued at $1.5 million to commercially develop its diagnostic assay aimed at multiple myeloma patient management, and a $200,000 phase I contract to develop a profiling diagnostic assay aimed at guiding therapies for patients with acute myelogenous leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.